Cambridge Cognition Holdings PLC are delighted to announce that both CANTAB Mobile and CANTAB Insight medical devices, designed for the assessment of cognitive health in clinical practice, have been approved for marketing in Australia by the Therapeutic Goods Administration (TGA) (ARTG No. 294119).
CANTAB Mobile and CANTAB Insight help healthcare practitioners to identify the earliest signs of clinically-relevant cognitive impairments, allowing intervention at an earlier stage.
Both medical devices are simple to set up and administer, with all assessments delivered via an iPad and featuring automated, standardised administration with voiceover guidance. Reports are generated immediately and scores are adjusted for age, gender and education level.
CANTAB Mobile
CANTAB Mobile detects the earliest signs of clinically-relevant memory impairment and differentiates depression in patients aged 50 to 90 years. There is also an optional functional assessment.
The average completion time is just 10 minutes.
